Scopio Labs

Scopio Labs’ suite of AI-powered digital imaging and analysis platforms supports laboratory experts with timely detection of blood-related medical conditions, expediting patients' access to life-saving treatments. Scopio’s platform analyzes thousands of blood cells to help laboratory professionals detect, treat, and monitor hematological-based conditions, including cancers, anemia, and infections. Scopio solves the age-old tradeoff between resolution and field of view, enabling unprecedented scale and depth in cell morphology. High-resolution imaging and embedded AI combine for more efficient workflow, contributing to better diagnostics across the continuum of care. The digital representation of the sample can be reviewed by experts in any location over a secure hospital network. These remote review capabilities mean laboratory experts are no longer limited by geography, and healthcare networks can provide faster and consistent diagnoses for their patients. Scopio Labs’ Full-Field Peripheral Blood Smear™ Application is FDA-cleared and CE-marked for use with the Scopio X100 and Scopio X100HT high-resolution scanners. In April 2024, the company was granted De Novo clearance by the FDA for its Full-Field Bone Marrow Aspirate™ (FF-BMA) Application, establishing a new regulatory category for all-digital bone marrow aspirate analysis software. The scalable platform, already being sold to labs around the world, meets the needs of a variety of large and small labs, and easily integrates with standard processes.

The details here are based on information received from, and verified solely by, the company.